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Abstract Glutamine (Gln) metabolism, initiated by its degra-
dation by glutaminases (GA), is elevated in neoplastic cells and
tissues. In malignant glia-derived tumors, GA isoforms, KGA
and GAC, coded by the GLS gene, are overexpressed, whereas
theGLS2-coded GAB and LGA isoforms, are hardly detectable
in there. Our previous study revealed that transfection of T98G
glioblastoma cells with GAB reduced cell proliferation and
migration, by a yet unknown mechanism not related to Gln
degradation. The question arose how simultaneous overexpres-
sion of GAB and inhibition of KGAwould affect glioblastoma
cell growth. Here, we used siRNA to silence the expression of
Gls in T98G cells which were or were not stably transfected
with GAB (TGAB cells). In both T98G and TGAB cell lines,
silencing of Gls with siRNAs targeted at different sequences
decreased cell viability and proliferation in a different, sequence-
dependent degree, and the observed decreases were in either cell
line highly correlated with increase of intracellular Gln (r>0.9),
a parameter manifesting decreased Gln degradation. The results
show that combination of negative modulation of GA isoforms
arising from GLS gene with the introduction of the GLS2 gene
product, GAB, may in the future provide a useful means to curb
glioblastoma growth in situ. At the same time, the results
underscore the critical role of Gln degradation mediated by
KGA in the manifestations of aggressive glial tumor phenotype.
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Introduction
Malignant gliomas are the most common brain tumors
in adults which despite diverse therapeutic efforts re-
main untreatable [1]. Hallmarks of glioma include high pro-
liferation, diffuse invasion, and resistance to chemo- and
radiotherapy.
Glutamine (Gln) is a central metabolite in many neoplastic
cells and tissues, including gliomas, and an increased
glutaminolysis is a characteristic feature of tumors, irrespec-
tive of their tissue origin [2]. Glutaminase (GA; EC 3.5.1.2) is
the enzyme catabolizing most of the tissue Gln to glutamate
(Glu) and ammonia. Two genes coding for GA have been
identified: the Gls gene encodes the kidney-type isoforms
(KGA and GAC) and the Gls2 gene encodes the liver-type
isoforms (LGA and GAB) [3]. KGA is expressed in all mam-
malian tissues except liver [4], while its alternatively spliced
variant, GAC, was found in the heart, pancreas, kidneys,
lungs, and breast cancer cells [5]. There are also two tran-
scripts arising from the Gls2 gene: LGA is expressed in liver
[4] and GAB is expressed in the brain, pancreas, leukaemic
cells [6], breast [7], and colorectal carcinoma cells [8].
Recently, it has been reported that GAB and LGA are
coexpressed in mammalian brain and liver by using an alter-
native transcription initiation mechanism and alternate pro-
moters [9]. Nuclear localization of GAB protein in the central
nervous system and its interactions with other proteins suggest
that the physiological role of this isoform may go beyond GA
activity [10, 11].
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Elevated glutaminolysis in cancer cells involves altered
expression and/or activity of GA isoforms [12]. The expression
pattern of distinct GA isoforms in several human-derived neo-
plastic cell lines and tissues allows hypothesizing that isoforms
encoded by GLS are upregulated in parallel with the prolifer-
ation rate, whereas isoforms encoded by GLS2 are related to a
quiescent, non-proliferating, cell state [6]. Noteworthy, GLS
overexpression induced by the oncogene c-Myc via miR-23
suppression is related to enhanced cell proliferation [13].
Silencing of GLS significantly decreased proliferation of pros-
tate cancer cells in vitro [13], Ehrlich ascites tumor cells in vitro
and in vivo [14], and T98G glioblastoma cells [15]. By con-
trast,GLS2 is a target gene of tumor suppressor p53 and plays a
pivotal role in mediating the functions of p53 in energy metab-
olism and antioxidant defense [16]. Overexpression ofGLS2 in
hepatocellular carcinoma cells reduced cell growth and colony
formation [16, 17].
In glioblastomas (WHO grade IV), the most malignant
brain tumors, high levels of GLS and only traces or lack of
GLS2 transcripts were found [18]. Likewise, human glioblas-
toma T98G cell line expresses high amounts of GLS tran-
scripts, while GLS2 transcripts are hardly detectable in these
cells. Transfection of T98G cells with a GAB cDNA sequence
diminished cell proliferation and survival [19].
An intriguing question arose whether or not combination of
GLS silencing and GLS2 overexpression would increase the
inhibition of cell proliferation and survival of glioblastoma
cells elicited by individual manipulations. To answer this
question, the expression of KGA and GAC isoforms was
knocked down in a human glioblastoma cell line that was
(TGAB cells) or was not (T98G cells) previously transfected
with GAB cDNA, respectively [19], and the two param-
eters describing the development of glioma were inves-
tigated in so treated cells. We employed graded inhibi-
tion of KGA and GAC in both T98G and TGAB cells to
analyze the correlation between the phenotypic changes and
the Gln content of the cells as a marker of the intensity of its
consumption.
Materials and methods
Cell lines and culture conditions
T98G human glioblastoma cell line purchased from American
Type Culture Collection and their derivative TGAB were
maintained in minimum essential medium (Sigma-Aldrich)
supplemented with 10 % FBS, 1 % nonessential amino acids,
and 1 % antibiotics (penicillin and streptomycin). Cultures were
maintained at 37 °C in a humidified atmosphere with 95 % air
and 5 % CO2. The culture medium for TGAB cell lines con-
taining the neomycin-resistance gene was supplemented with
0.5 mg/ml G418 (Sigma-Aldrich). The expression of the Gls2
gene in both cell lines was monitored by RT-PCR as described
previously [19].
Construction of siRNAs
Silencer siRNA Construction Kit (Ambion) was used to design
and construct siRNAs. Briefly, five target sequences (Table 1)
within the human Gls mRNA sequences (GenBank accession
no.: NM_014905.4 and NM_001256310.1 for KGA and GAC
transcript, respectively) were chosen according to the manufac-
turer’s protocol. All the chosen sequences contain less than 17
contiguous base pairs of homology to other coding sequences
within the human genome. The sense and antisense template
DNA oligonucleotides for each of five siRNAs (termed siGls3–
7) were synthesized (IBB, PAS) and used for in vitro transcrip-
tion. Obtained siRNAs were purified and quantified with
NanoDrop 2000 UV/Vis Spectrophotometer. To control for
nonspecific events, scrambled sequence oligonucleotides (scr)
with the same base composition as the antisense oligonucleo-
tide, but in arbitrary order, were employed.
Transient transfection
Transient transfection of T98G cells and TGAB cells
was performed with Lipofectamine 2000 (Invitrogen),
according to the manufacturer’s protocol. Briefly, the
day before transfection, cells were seeded in antibiotic-
free growth medium for 24 h. Next, complexes contain-
ing Lipofectamine and siGls3–7 or scr were directly added
into the media. The knockdown of GLS was measured by
quantitative real-time PCR and Western blot 48 h after
transfection.
RNA isolation and RT-PCR
Total RNA from the transfected cells was extracted using a
guanidinium-thiocyanate-based commercial kit (TRI-Reagent,
Sigma). Two micrograms of RNA was digested with DNaseI
(Invitrogen) and reverse-transcribed using a High-Capacity
Table 1 Sequences targeted by anti-Gls siRNA








GenBank accession numbers NM_014905.4 and NM_001256310.1 refer
to KGA and GAC transcripts, respectively
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cDNA Reverse Transcription Kit (Applied Biosystems)
according to the manufacturer’s protocol.
Real-time PCR
Real-time PCR analyses were conducted using TaqMan Gene
Expression Assays and TaqMan Universal PCR MasterMix
(Applied Biosystems) according to the manufacturer’s proto-
col. The assays IDs are listed in Table 2. The reactions were
incubated in a 96-well optical plates at 95 °C for
10 min, followed by 45 cycles of 95 °C for 15 s and 60 °C
for 1 min using an Applied Biosystems 7500 Sequence
Detection System. Relative expression was calculated
using the ΔΔCT method [20] and normalized to the expres-
sion β-actin.
Western blot analysis
The cells were harvested and sonicated in radioimmuno-
precipitation assay lysis buffer supplemented with cocktails
of protease and phosphatase inhibitors (Sigma-Aldrich).
Lysates were centrifuged at 12,000×g for 10 min at 4 °C.
Protein concentration was determined with BCA Protein
Assay Kit (Thermo Scientific Pierce). Samples of 30 μg total
protein were subjected to sodium dodecyl sulfate (SDS)-
PAGE. Resolved proteins were transferred to nitrocellulose
membrane and probed with specific primary antibodies: anti-
Gls or anti-GAC (Proteintech) and secondary antibody con-
jugated to horseradish peroxidase (Sigma-Aldrich). Blots
were developed with SuperSignal West Pico chemilumines-
cence substrate (Thermo Scientific Pierce). For loading con-
trol, membranes were stripped and reprobed with a human-
specific antibody against GAPDH (Sigma-Aldrich).
Densitometric analysis was done using G:Box system and
GeneTools software (Syngene).
Intracellular Gln and Glu assays
Gln and Glu in cell supernatants were determined using HPLC
as described previously [19]. Briefly, 48 h post-transfection,
T98G and TGAB cells were washedwith PBS, incubated in 5-
sulfosalicylic acid for 5 min and centrifuged at 12,000×g for
5 min. The level of amino acids in supernatants was analyzed
using HPLC with fluorescence detection. Protein content was
measured in the supernatants using the method described by
Bradford [21].
Cell viability
Cell viability was determined by means of a 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) con-
version as described previously [19]. Briefly, equal numbers
of T98G and TGAB cells (4×104/well) were seeded in 24-
well plates and incubated for 24 h. After this time, the cells
were transfected with siGls3–7 or scr siRNA and cultured for
further 48 h. Next, the medium was removed and the cells
were washed with PBS and incubated in the culture medium
with MTT solution at the final concentration of 0.5 mg/ml for
15 min to allow the conversion of MTT into formazan. Then,
the medium was replaced with 5 % SDS and absorbance was
read at 570 nm using Elisa Bio-Rad Microplate Reader. Cell
viability was expressed as a mean of four replicate wells from
four independent experiments.
Cell proliferation assay
DNA synthesis as a marker for cellular proliferation was
measured by bromodeoxyuridine (BrdU) incorporation using
the Cell Proliferation Elisa BrdU (colorimetric) assay (Roche)
according to the manufacturer’s instruction. Briefly, equal
numbers of T98G and TGAB cells (5103/well) were seeded
in 96-well plates and incubated for 24 h. After this time, the
cells were transfected with siGls3–7 or scramble siRNA and
cultured for further 48 hours. Next, BrdU was added for 2 h,
and then cells were fixed for 30 min and incubated with BrdU
antibody for 90 min. The absorbance values were measured at
415 nm using Elisa Bio-Rad Microplate Reader. Cell prolif-
eration was expressed as a mean of four replicate wells from
six independent experiments.
Statistical analysis
All experiments described above were repeated at least four
times. Results are reported as means and standard deviations.
Statistical significance of comparisons was based on one-way
ANOVA followed by Tukey’s test.
Results
To explore the role of GLS GA isoforms in T98G and TGAB
cells, we transiently knocked down both transcripts arising
from the GLS gene using five siRNAs targeting KGA and
GAC sequences in different sites. The primary assumption was
that all five siRNAs will silence both transcripts arising from
theGLS gene with equal potency. The level of KGA transcript
was decreased by more than 80 % in case of treatment with
siGls3–5 and more than 70 % in case of treatment with siGls6
and siGls7 (Fig. 1a, b). The reduction of GAC transcript level
was less pronounced and ranged from approx. 80 % in case of
Table 2 TaqMan gene expression assays used for real-time PCR
Transcript Assay ID GeneBank sequence Exon boundary
KGA Hs01014019_m1 NM_014905.4 17–18
GAC Hs01022166_m1 NM_001256310.1 14–15
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treatment with siGls3–5 and approximately 60 % in case of
treatment with siGls6 and siGls7 (Fig. 1c, d). There was no
significant difference between the nontransfected cells and the
cells transfected with scr siRNA indicating that the transfection
process itself had no influence on the GLS expression. As no
differences were observed between the effectiveness of distinct
scrambled siRNAs, only the results obtained for scrambled
oligonucleotide 3 (scr3) are illustrated.
Western blot analyses, using antibodies specific to the
KGA or GAC isoform, showed a decreased levels of either
protein in T98G (Fig. 2a, c, e) and TGAB (Fig. 2b, d, f) cell
lines. Again, siGls3-5 presented higher effectiveness than
siGls6 and siGls7.
Next, we evaluated the effects of the presence or absence of
each GA on the intracellular levels of Gln content in the
differently transfected cells. Consistent with our previous study
[19], cells enriched in GLS2 (TGAB) contained ∼2 times less
Gln and than T98G cells (Fig. 3). In both cell lines, reduction of
GLS content by treatment with siGls3–5 increased Gln level,
while the effects of siGls6 and siGls7 treatments on Gln level
were insignificant (Fig. 3). Of note, in TGAB cells treated with
siGls3–5 the intracellular Gln amount was significantly lower
than in T98G counterparts. No differences in Gln levels were
observed between untreated cells and cells treated with scr-
RNA. Glu levels decreased insignificantly after treatment with
each of the five siRNAs (data not shown; Glu level was in all
cases present in a manifold excess of Gln).
MTT test showed a significant reduction of viable cell mass
following GLS knockdown by siRNA treatment in both cell
lines (Fig. 4). Treatment of T98G and TGAB cells with
siGls3–5 decreased cell viability by ∼50 and ∼65 %, respec-
tively, while in the case of siGls6 and siGls7 the reduction
amounted to ∼40 and ∼20 % in T98G and TGAB cells,
respectively. No differences in cell viability were observed
between cells treated with scr-RNA and untreated cells.
To examine the influence of the GLS knockdown on cell
proliferation, BrdU incorporation was monitored in T98G and
TGAB cells after treatment with siGls3–7. In contrast to
untreated counterparts and cells treated with scr siRNA, the
percentage of BrdU-incorporated cells was reduced by nearly
65 % in T98G and 60 % in TGAB cells after transfection with
siGls3–5, respectively, while treatment with Gls6 and Gls7
decreased proliferation of both cell lines by∼40% (Fig. 5a, b).
Again, the values of absorbance were lower in case of TGAB
cells than in case of T98G cells.
Next, we studied how the phenotypic characteristics of cells
treated in different GA-modifying paradigms correlated with
the intracellular Gln content evoked by the treatments. In both
cell lines, viable cell mass negatively correlated with the level
of intracellular Gln (r =−0.8747, p <0.05; r =−0.9937, p <
0.0001 for T98G and TGAB, respectively) (Fig. 6a, b).
Similarly, proliferation negatively correlated with the level of
intracellular Gln (r =−0.8925, p <0.01; r =−0.9774, p =0.0001
for T98G and TGAB, respectively) (Fig. 6c, d).
Discussion
Elevated Gln metabolism fulfills the demands of increased
proliferation and growth displayed by neoplastic cells of
Fig. 1 Silencing of GLS
decreases the level of KGA and
GAC transcripts. Relative
expression of KGA (a , b) and
GAC (c , d) transcripts measured
vs beta-actin expression. The
results are mean ± SD for five
mRNA isolations from each cell
line. *p <0.01 vs untreated or
treated with scrambled siRNA
cells as tested with one-way
ANOVA followed by Tukey’s test
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different origin [2]. Consistently, upregulated expression and
activity of GA catabolizing Gln is a hallmark of these cells
[12]. Studies conducted during the past decade have demon-
strated that GA isoforms play opposite roles in tumorigenesis.
In the different native neoplastic cells or cultured cell lines
examined so far, the GLS isoforms are associated with cell
proliferation, whereas the GLS2 isoforms are attributed to
resting or quiescent cell states [6, 8]. Knocking down of
GLS gene in the mouse mammary tumor cells [14], the
MCF-7 breast cancer cells [22], and glioblastoma cells [15]
led to a reversion of the transformed phenotype. Similar
phenotype reversion was attained by overexpression of the
GLS2 gene in nonsmall-cell lung carcinoma cells [17], while
exogenous GLS2 expression reduces cell colony formation in
human hepatocellular carcinoma and lung cancer cell lines
[16]. Likewise, our previous studies revealed that stable trans-
fection of a full cDNA sequence encoding GAB protein (a
GLS2 isoform) reduces proliferation and migration of glio-
blastoma T98G cell line [19] and sensitizes transfected cells
(TGAB cells) to the alkylating chemotherapeutics [23].
Here, we used five siRNAs complementary to different sites
within mRNA for KGA and GAC transcripts arising fromGLS
gene. Three of these siRNAs inhibited the expression of both
transcripts with ∼80 % efficiency, while two of them reduced
the expression by ∼60 %. The reasons for discrepancy between
the potency of distinct siRNAs are unknown. Most likely, it
results from differences in target sequence accessibility, as
some regions of mRNA may be highly structured or bound
by some proteins [24].
In this study,GLS silencing significantly decreased viability
and proliferation of glioblastoma T98G cells which do not
express appreciable amounts of GA isoforms arising from
GLS2 gene. This effect is likely to be representative for other
glioblastoma-derived cell lines or glioblastomas that possess
relatively low levels of the Gls2 gene product. The level of
viability and proliferation highly negatively correlated with the
level of intracellular Gln, reinforcing the importance of this
amino acid for growth of glioblastoma cells. These results are
consistent with data obtained by other groups [15, 25].
To our knowledge, this is the first study documenting the
effect of GLS silencing in glioblastoma cells expressing sub-
stantial amount of GAB (TGAB cells). Similarly to T98G cells,
TGAB cells treated with anti-GLS siRNA displayed significant
decrease in proliferation and viability and both parameters were
negatively correlated with the level of intracellular Gln. The
basic function of proteins encoded by both GLS and GLS2
Fig. 2 Silencing of GLS
decreases the level of KGA and
GAC proteins. The graphs show
quantification of KGA (a , b) or
GAC (c , d) band intensity
normalized to GAPDH. The
results are mean ± SD for four
protein isolations from each cell
line. *p <0.01 vs untreated or
treated with scrambled siRNA
cells as tested with one-way
ANOVA followed by Tukey’s
test. In the lowest part,
representativeWestern blots show
amounts of KGA, GAC, and
GAPDH in protein extracts from
T98G (e) or TGAB (f) cells
treated with siGls3–7
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genes is to metabolize Gln. Therefore, lack of any GA isoform
resulting in uppermost intracellular Gln level should diminish
cell growth most effectively, while graded decrease in Gln level
should entail increase of cell growth. However, it was not
exactly the case in this study. In spite of significantly lower
level of intracellular Gln, TGAB cells displayed reduced
growth as compared to T98G cells. Moreover, TGAB cells
treated with anti-GLS siRNA presented lower proliferation
and viability, although the level of intracellular Gln in these
cells was significantly diminished as compared to T98G so
treated. This results support the earlier observations that
GLS2 isoforms play opposite role to GLS isoforms with regard
to promotion of cell proliferation [6, 8]. Of note, the propor-
tional decrease of viability and proliferation evoked by GLS
silencing was higher in T98G than in TGAB cells. This last
result is consistent with the observation TGAB cells overex-
pressing GLS2 already acquired a more differentiated and less
malignant phenotype [19].
The physiological meaning of simultaneous existence of GA
isoforms in one cell type remains unknown. However, there is a
growing body of evidence that proteins arising from these two
genes are involved in different signaling pathways. The hypoth-
esis that GAB is a multifunctional protein fulfilling roles other
than enzymatic is originally based on finding that this isoform
can interact with PDZ-containing proteins [26] and may be
localized in the neuronal nuclei [10]. Later studies showed that
GLS2 is a target gene of p53 tumor suppressor to mediate the
role of p53 in cellular energy metabolism and antioxidant
defense mechanisms [16, 17]. Very recent findings confirmed
more significant role of GAB than KGA in controlling redox
status in neoplastic cells [25, 27]. On the contrary, GLS gene
has been demonstrated to be regulated by c-Myc oncogene and
upregulated in parallel with cancer cell proliferation [13].
In conclusion, the key finding of this study is that GLS
silencing reduces proliferation and viability of glioblastoma
cells and strengthen the antiproliferative effect evoked by
GLS2 overexpression. As such, the finding underscores the
critical role of Gln degradation in the manifestation of aggres-
sive glial tumor phenotype. From the clinical perspective, it is
to be hoped that that combination of modulation of expression
and/or activity of GA isoforms arising from GLS and GLS2
gene products may in the future provide a useful treatment
modality to prevent glioblastoma growth.Wewant also to stress
the fact that glioblastoma TGAB cells overexpressingGLS2 are
more susceptible to chemotherapy with alkylating agents [23].
A more detailed analysis of this phenomenon is currently
conducted in our laboratory with derivatives of T98G and
TGAB cells stably transfected with a vector carrying anti-GLS
Fig. 3 Silencing ofGLS increases
intracellular level of Gln in T98G
(a) and TGAB (b) cells. T98G
and TGAB cells were transfected
with siGls3–7. The level of
intracellular Gln was measured at
48 h post-transfection. The results
are mean ± SD for four
independent determinations for
each cell line. *p<0.05 vs
untreated cells and treated with
scrambled siRNA (scr3);
**p<0.05 vs T98G counterparts
as tested with one-way ANOVA
followed by Tukey’s test
Fig. 4 Silencing of GLS
decreases survival of T98G (a)
and TGAB (b) cells. T98G and
TGAB cells were transfected with
siGls3–7. Mitochondrial activity
was assessed by the MTT test at
48 h post-transfection. The results
are mean ± SD for four
independent determinations for
each cell line. *p <0.05 vs
untreated cells and treated with
scrambled siRNA (scr3) as tested
with one-way ANOVA followed
by Tukey’s test
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sequence. Preliminary experiments indicate that until the first
passage T98G cells transfected with such a vector proliferate
very slowly, while after the first passage their proliferation
increases, although it is still significantly reduced as compared
to the non-transfected counterparts. This observation could be a
consequence of a compensatory anaplerotic mechanism de-
scribed by Cheng et al. [15], allowing the cells to use glucose
instead of Gln. Interestingly, a study of tumor metabolism
in vivo using an orthotopic mouse model of primary human
glioma revealed that the tumors and surrounding brain showed
Fig. 5 Silencing of GLS
decreases proliferation of T98G
(a) and TGAB (b) cells. T98G
and TGAB cells were transfected
with siGls3–7. Proliferation was
assessed by the BrdU test at 48 h
post-transfection. The results are
mean ± SD for six independent
determinations for each cell line.
*p <0.05 vs untreated cells and
treated with scrambled siRNA
(scr3) as tested with one-way
ANOVA followed by Tukey’s test
Fig. 6 Correlations between Gln
level and cell viability or
proliferation. a Correlation
between Gln level and results of
MTT assay in T98G cells
(Pearson’s correlation coefficient:
r =−0.8747, p =0.01). b
Correlation between Gln level
and results of MTT assay in
TGAB cells (r =−0.9937,
p <0.0001). c Correlation
between Gln level and results
of BrdU assay in T98G cells
(r =−0.8925, p <0.01). d
Correlation between Gln level
and results of BrdU assay in
TGAB cells (r =−0.9774,
p =0.0001)
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metabolic differences, notably the accumulation of a large Gln
pool within the tumors [28]. On the contrary, TGAB cells
transfected with a vector carrying anti-GLS sequence present
strongly diminished, but more stable level of proliferation sug-
gesting that they do not have to adapt to Gln-free conditions.
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